Stocks / NASDAQ / NxStage Medical, Inc.

NxStage Medical, Inc.

Our Opinion

NxStage Medical, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.

Supporting Evidence:

The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.

“Our ability to successfully market our products for the treatment of kidney failure could also be adversely affected by pharmacological and technological advances in preventing the progression of chronic ESRD and/or in the treatment of acute kidney failure, technological developments by others in the area of dialysis, the development of new medications designed to reduce the incidence of kidney transplant rejection and progress in using kidneys harvested from genetically-engineered animals as a source of transplants.” (Page 9) Read the full document

Company Description

NxStage Medical, Inc. operates as a medical device company which manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its primary product, the NxStage System One, was designed to satisfy an unmet clinical need for a system that can deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy to use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis clinics. The company also markets its product NxStage System One to hospitals for treatment of acute kidney failure and fluid overload. The company operates through the following segments: System One, In-Center and Services. NxStage Medical was founded by Jeffrey H. Burbank in December 1998 and is headquartered in Lawrence, MA. [Source: MarketWatch]

Company Website: